Immunosuppressive effects of new thiophene-based K1.3 inhibitors.

Voltage-gated potassium channel K1.3 inhibitors have been shown to be effective in preventing T-cell proliferation and activation by affecting intracellular Ca homeostasis. Here, we present the structure-activity relationship, K1.

Correction: Gubič et al. Design of New Potent and Selective Thiophene-Based K1.3 Inhibitors and Their Potential for Anticancer Activity. 2022, , 2595.

In the original publication [...

New Diarylamine K10.1 Inhibitors and Their Anticancer Potential.

Expression of the voltage-gated potassium channel K10.1 (Eag1) has been detected in over 70% of human cancers, making the channel a promising new target for new anticancer drug discovery. A new structural class of K10.

Design of New Potent and Selective Thiophene-Based K1.3 Inhibitors and Their Potential for Anticancer Activity.

The voltage-gated potassium channel K1.3 has been recognized as a tumor marker and represents a promising new target for the discovery of new anticancer drugs. We designed a novel structural class of K1.

Discovery of K 1.3 ion channel inhibitors: Medicinal chemistry approaches and challenges.

The K 1.3 voltage-gated potassium ion channel is involved in many physiological processes both at the plasma membrane and in the mitochondria, chiefly in the immune and nervous systems. Therapeutic targeting K 1.

3D Pharmacophore-Based Discovery of Novel K10.1 Inhibitors with Antiproliferative Activity.

(1) Background: The voltage-gated potassium channel K10.1 (Eag1) is considered a near- universal tumour marker and represents a promising new target for the discovery of novel anticancer drugs. (2) Methods: We utilized the ligand-based drug discovery methodology using 3D pharmacophore modelling and medicinal chemistry approaches to prepare a novel structural class of K10.